STOCK TITAN
  1. Home
  2. News
  3. BNOX

Bionomics Limited American Depository Shares - BNOX STOCK NEWS

Welcome to our dedicated page for Bionomics American Depository Shares news (Ticker: BNOX), a resource for investors and traders seeking the latest updates and insights on Bionomics American Depository Shares stock.

Bionomics Limited American Depository Shares (symbol: BNOX) is a global clinical-stage biopharmaceutical company dedicated to developing novel treatments for serious diseases. The company's primary focus lies in treating central nervous system (CNS) disorders such as anxiety, depression, and Alzheimer's disease, as well as various forms of cancer.

Bionomics boasts a highly productive drug discovery platform, including its proprietary Multicore® chemistry capability, which fuels its diverse pipeline of drug candidates. The company's portfolio ranges from early-stage to advanced clinical development programs, positioning Bionomics as a leader in innovative drug discovery.

A key strength of Bionomics is its strategic partnerships with large pharmaceutical companies. These collaborations enable Bionomics to expedite the development and market introduction of its drug candidates, allowing the company to concentrate on its core strength of innovative research and discovery.

Among its recent achievements, Bionomics is progressing its Phase 2b trial of BNC210, a promising treatment for Post-Traumatic Stress Disorder (PTSD). The trial aims to evaluate the safety and efficacy of 900 mg BNC210 administered twice daily as monotherapy for PTSD. The trial involves 212 participants across 27 sites in the United States and 7 sites in the United Kingdom.

Financially, Bionomics generates all of its revenue from Australia, with a robust growth phase backed by substantial research and development investments. The company is committed to providing better treatment options for diseases with unmet medical needs, driven by a team of experts dedicated to making a difference in patients' lives.

For the latest updates and detailed information about Bionomics Limited, please visit their official website at www.bionomics.com.au.

News

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

Rhea-AI Summary
Bionomics (Nasdaq: BNOX) announced positive Phase 2b trial results for BNC210 in treating post-traumatic stress disorder (PTSD), showing statistically significant improvements with a favorable safety profile. BNC210 demonstrated rapid onset of clinical efficacy and sustained effects, meeting primary and secondary endpoints. The trial data supports BNC210 as a potential highly differentiated treatment with a novel mechanism of action, positioning it as a promising therapy for PTSD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.94%
Tags
clinical trial
-
News

Bionomics to Present at the 2024 BIO CEO & Investor Conference

Rhea-AI Summary
Bionomics Limited (BNOX) to present at 2024 BIO CEO & Investor Conference on February 27, 2024, providing updates on BNC210, a Phase 3 ready asset for social anxiety disorder and post-traumatic stress disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences
-
News

Bionomics Provides a Review of 2023 and of 2024 Plans

Rhea-AI Summary
Bionomics Limited (Nasdaq: BNOX) announced positive Phase 2b data for BNC210 in treating PTSD and SAD, with plans for a registrational study and strategic partnerships. The Company also reported successful clinical trials, strategic partnerships, and financial highlights for 2023, with an optimistic outlook for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
News

Bionomics to Present at Biotech Showcase™ 2024

Rhea-AI Summary
Bionomics Limited (Nasdaq: BNOX) will provide an update on its leading asset BNC210 and their partnership strategy at the Biotech Showcase™ 2024 in San Francisco. Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics, will present an update on BNC210, a Phase 3 ready α7 nicotinic receptor negative allosteric modulator with the potential to be first- and best-in-class in social anxiety disorder and post-traumatic stress disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
conferences
-
News

Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting

Rhea-AI Summary
Bionomics Limited (BNOX) announced the psychometric analysis of Subjective Units of Distress Scale (SUDS) as a valid, reliable, and sensitive tool for assessing anxiety in social anxiety disorder (SAD) clinical trials. The presentation, held at the 2023 American College of Neuropsychopharmacology Annual Meeting, highlighted the successful Phase 2 PREVAIL trial of BNC210 in SAD, where BNC210 demonstrated reduced anxiety and was well tolerated. The company also agreed on the plan for a registrational study of BNC210 in SAD, with SUDS as the primary efficacy endpoint. The upcoming Phase 3 trial is expected to begin in Q1’24.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
none
-
News

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

Rhea-AI Summary
Bionomics Limited announces positive topline results from its Phase 2b ATTUNE trial of BNC210 for the treatment of PTSD. The trial met its primary endpoint of a statistically significant reduction in total PTSD symptom severity at 12 weeks. Secondary endpoints showed improvements in depressive symptoms and sleep. The company plans to engage with the FDA to discuss the registrational path for BNC210 in PTSD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
242.13%
Tags
clinical trial
News

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD

Rhea-AI Summary
Bionomics collaborates with MSD to develop α7 nAChR PAMs for Alzheimer's Disease treatment. MSD presents data on MK-4334, a candidate derived from Bionomics' BNC375, at a recent conference. BNC375 shows promising results in animal models. MSD funds research and development, generating $20M upfront and $10M milestone payment for Phase 1. Bionomics eligible for up to $465M in additional milestone payments and royalties on net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.14%
Tags
none
-
News

Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210

Rhea-AI Summary
The Phase 2b ATTUNE study of BNC210 for PTSD is completed, with topline results expected by September 2023. An EoPh2 meeting with the FDA is scheduled for September 2023 to review results from the Phase 2 PREVAIL study for SAD and discuss a Phase 3 program. Bionomics will delist from the Australian Securities Exchange on August 28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.83%
Tags
clinical trial
-
News

Quarterly Activities and Cashflow Report

Rhea-AI Summary
Bionomics Limited (BNOX | BNO) Releases Quarterly Cashflow Report and Announces Key Clinical Trial Updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.14%
Tags
none
News

Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX)

Rhea-AI Summary
Bionomics Limited has submitted a request to be removed from the official list of the ASX and focus on a primary listing on the NASDAQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.92%
Tags
none

FAQ

What is the current stock price of Bionomics American Depository Shares (BNOX)?

The current stock price of Bionomics American Depository Shares (BNOX) is $0.1969 as of November 1, 2024.

What is the market cap of Bionomics American Depository Shares (BNOX)?

The market cap of Bionomics American Depository Shares (BNOX) is approximately 3.4M.

What does Bionomics Limited specialize in?

Bionomics Limited specializes in developing treatments for central nervous system disorders and various forms of cancer.

What is BNC210?

BNC210 is a drug candidate being developed by Bionomics for treating Post-Traumatic Stress Disorder (PTSD) and is currently in Phase 2b clinical trials.

Where does Bionomics generate its revenue?

Bionomics generates all of its revenue from Australia.

How does Bionomics accelerate drug development?

Bionomics accelerates drug development through strategic partnerships with large pharmaceutical companies, which help in advancing their drug candidates through the later stages of clinical development and into the market.

What is the Multicore® chemistry capability?

Multicore® is Bionomics' proprietary chemistry platform that supports its drug discovery efforts, contributing to the development of a diverse pipeline of drug candidates.

What diseases is Bionomics targeting?

Bionomics targets central nervous system disorders like anxiety, depression, and Alzheimer's disease, as well as various cancers.

Where can I find more information about Bionomics' latest news?

For the latest news and updates about Bionomics, visit their official website at www.bionomics.com.au.

What are the key criteria for the BNC210 Phase 2b trial participants?

Participants must be 18-75 years old, have a current PTSD diagnosis with a CAPS-5 total symptom severity score of ≥30, and ≤25% decrease in CAPS-5 score from screening to baseline.

How does Bionomics contribute to the biopharmaceutical industry?

Bionomics contributes to the biopharmaceutical industry by developing innovative treatments for diseases with inadequate options, advancing the field of CNS disorders and cancer treatment.

What is the significance of Bionomics' drug discovery platforms?

Bionomics' drug discovery platforms, including Multicore®, are crucial for developing a diverse range of innovative drug candidates, enhancing their ability to address unmet medical needs.

Stock BNOX logo
Bionomics Limited American Depository Shares

Nasdaq:BNOX

BNOX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

BNOX Stock Data

3.41M
3.12B
38.23%
16.93%
0.08%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
EASTWOOD SA